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Abstract
The retinal pigment epithelium (RPE) plays a central role in neuroretinal homoeostasis
throughout life. Altered proteolysis and inflammatory processes involving RPE con-
tribute to the pathophysiology of age‐related macular degeneration (AMD), but the
link between these remains elusive. We report for the first time the effect of advanced
glycation end products (AGE)—known to accumulate on the ageing RPE's underlying
Bruch's membrane in situ—on both key lysosomal cathepsins and NF‐κB signalling in
RPE. Cathepsin L activity and NF‐κB effector levels decreased significantly following
2‐week AGE exposure. Chemical cathepsin L inhibition also decreased total p65 pro-
tein levels, indicating that AGE‐related change of NF‐κB effectors in RPE cells may be
modulated by cathepsin L. However, upon TNFα stimulation, AGE‐exposed cells had
significantly higher ratio of phospho‐p65(Ser536)/total p65 compared to non‐AGEd
controls, with an even higher fold increase than in the presence of cathepsin L inhibi-
tion alone. Increased proportion of active p65 indicates an AGE‐related activation of
NF‐κB signalling in a higher proportion of cells and/or an enhanced response to TNFα.
Thus, NF‐κB signalling modulation in the AGEd environment, partially regulated via
cathepsin L, is employed by RPE cells as a protective (para‐inflammatory) mechanism
but renders them more responsive to pro‐inflammatory stimuli.
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1 | INTRODUCTION
The retinal pigmented epithelium (RPE) is a monolayer of highly spe-
cialized cells that underlie the neuroretina and help maintain retinal
homoeostasis.1 Together with the underlying support matrix (Bruch's
membrane, BrM), the RPE forms a selective barrier between the
neuroretina and the choroid. In addition, the BrM is involved in mod-
ulation of RPE differentiation, migration and adhesion thus underpin-
ning the role of the RPE–BrM complex in normal eye physiology.2-4
The longevity of RPE cells—owing to their terminally differenti-
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age‐related changes which in turn can impact on specialized cellular
processes. The RPE undergoes several structural changes with age
including loss of melanin, accumulation of lipofuscin and atrophy of
RPE microvilli.6-8 The BrM also displays age‐related structural and
physiological changes such as an increase in overall thickness and an
increase in phospholipids, triglycerides and fatty acids content. In
addition, collagen components of the BrM show increased cross‐link-
ing and decreased solubility.9-12 Gaining a better understanding of
the ageing process and its impact on RPE cellular function has
become a key area of research in age‐related macular degeneration
(AMD), the most common cause of blindness in developed countries,
whose pathophysiology is believed to be directly linked to RPE
impairment.13,14
An important phenomenon of ageing in all tissues is the accumu-
lation of advanced glycation end products (AGE).15 AGE are a group
of heterogeneous reaction products formed between reducing sugars
and either lipids or the free amino groups on biomolecules such as
proteins.15,16 AGE accumulate on long‐lived extracellular matrix pro-
teins such as collagen, where by altering macromolecular structure
and function, they contribute to the development and progression of
age‐related diseases.16,17 AGE adducts are known to accumulate in
the BrM with age and their presence has been associated with
AMD.18-20 Exposure to AGE alters the gene expression profile of
cultured RPE cells, which in turn impacts their functional capacity. It
has been shown for example, that RPE cells grown on AGE‐modified
substrate have been shown to have down‐regulated expression of
cathepsins D, G and S.19
Cathepsins, such as the cysteine proteases cathepsins L and S and
the aspartic protease cathepsin D govern lysosomal function.21,22
Cathepsins B, D, L and S are known to be key regulators of autop-
hagy.23-25 Within RPE cells, cathepsins D and S are involved in the
degradation of photoreceptor outer segments (POS) and thus play a
direct role in the maintenance of visual homoeostasis.26,27 In addition,
the activity of cathepsins has been linked to the modulation of sig-
nalling pathways; notably cathepsin L was shown to be involved in the
regulation of the nuclear factor kappa B (NF‐κB) signalling path-
way.28,29 NF‐κB is a transcription factor that participates in the
expression of many genes such as the pro‐inflammatory cytokines
interleukin‐1β (IL‐1β) and interleukin 18 (IL‐18).30, 31 Both IL‐1β and IL‐
18 are synthesized as precursors that require proteolytic maturation
by caspase‐1 which must first be activated by multi‐protein complexes
known as inflammasomes.32 As inflammation plays a major role in the
pathogenesis of AMD,33 dysregulation of cathepsin activity might be a
contributing factor to RPE dysfunction and AMD pathology.
Importantly in this context, cathepsins have been shown to be
susceptible to age‐related alterations. An increase in cathepsin D
activity along with a decrease in cathepsin L activity was docu-
mented in the ageing rat brain.34 The activity of cathepsins such as
L and H significantly decreased in kidney proximal tubule cell line
LLC‐PK1 after AGE exposure.35 A decrease in mRNA expression of
lysosomal enzymes cathepsin S, cathepsin G, acid phosphatase, β‐
galactosidase and β‐mannosidase was observed in RPE cells exposed
to AGE; cathepsin D activity levels also decreased in RPE cells after
AGE exposure.19 Moreover, in addition to cathepsins, AGE exposure
was shown to modulate NF‐κB activity through activation of their
receptor RAGE.36
Given the evidence that cathepsins can regulate NF‐κB activity, it
is hypothesized that AGE adducts could exert their effects on the
NF‐κB signalling pathway and thus on processes such as inflammation,
through modulation of cathepsins activity. This study tested the above
hypothesis in RPE cells, making use of an in vitro model of RPE cells
exposed to AGE‐modified basement membrane mimicking an ageing
BrM.19 Specifically, we analysed the effects of AGE on expression and
activity of RPE‐expressed cathepsins alongside endogenous levels of
effectors of the NF‐κB signalling pathway and investigated the link
between cathepsin L and NF‐κB regulation. We demonstrate that fol-
lowing AGE exposure, both cathepsin L expression and activity, as well
as protein levels of key NF‐κB pathway effectors, are reduced in RPE
cells. Furthermore, we also show that cathepsin L is involved in regula-
tion of NF‐κB regulation in RPE cells indicating the decrease of NF‐κB
effectors following exposure to AGE may at least in part be because of
changes in cathepsin L levels. We propose that the alterations of
cathepsin L expression and activity and the associated dampening of
the NF‐κB signalling serve as an early cellular protective mechanism in
the ageing RPE, but may contribute to the environment in which cells
are more vulnerable and receptive to subsequent or persistent pro‐
inflammatory stimuli.
2 | MATERIALS AND METHODS
2.1 | RPE cell culture and AGE modification of
extracellular matrix (ECM)
An authenticated human RPE cell line ARPE‐19 (ATCC, Rockville,
Maryland, USA) was maintained in 1:1 mixture of DMEM/F12
(Sigma, Dorset, UK) media supplemented with 10% FCS for the first
4 days in culture after which the cells were maintained for long‐term
culture in medium containing 2% FCS leading to the formation of
stable RPE monolayers.
Experiments were carried out in standard 6‐well or 12‐well plates,
previously coated with a solubilized basement membrane matrix
extract, Matrigel (MG)™ (BD Biosciences, Oxford, UK) for 1 hour at
37°C. MG™, rich in common basement membrane matrix components,
was used to mimic the innermost layer of the BrM. To mimic an aged
phenotype of BrM, the Matrigel coat was AGE‐modified as previously
described.19,37 Briefly, AGE adduct formation was induced by incubat-
ing the MG™ substrate in the presence of 100 m mol L−1 glycolalde-
hyde (Sigma, Dorset, UK) at 37°C for 4 hours, followed by thorough
washing with PBS. Termination of the glycation reaction was achieved
by incubating the MG™ with 50 m mol L−1 sodium borohydride
(Sigma, Dorset, UK) at 4°C overnight, followed by thorough washing.
For control wells, MG™ was treated in the same way, with the excep-
tion of glycolaldehyde substitution with PBS. The degree of AGE mod-
ification and collagen cross‐linking in this ageing in vitro model was
previously described.37 For the 6‐well plate experimental set‐up,
ARPE‐19 cells were seeded on control and AGE‐modified MG™ at a
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cell density of 1 x 104 cells per well; cell number was appropriately
rescaled for 12‐well plate experiments.
2.2 | Cathepsin L inhibition
ARPE‐19 cells were seeded at a density of 1 x 105 on 6‐well plates
and allowed to grow in culture for 4 days in DMEM/F12 (Sigma, UK)
with 10% FCS to reach confluency. The confluent cells were treated
with 40uM Cathepsin L Inhibitor III (Merck Millipore, Darmstadt,
Germany) for 8 hours at 37°C and followed by thorough washing
with PBS. Cells were lyzed in lysis buffer38 and subjected to SDS
polyacrylamide electrophoresis for analysis of protein expression by
Western blotting as described below.
2.3 | TNFα treatment
Following the respective times for cathepsin L inhibition or AGE
exposure, ARPE‐19 cells were treated with 10 ng/mL TNFα (Thermo-
Fisher Scientific, Waltham, USA) for a further 2 hours. The control
cells were not treated with TNFα. Cells were then thoroughly
washed with PBS after which cell lysates were collected following
the addition of lysis buffer38 to the wells. As the activation of NF‐κB
signalling pathway in Hela cells in response to TNFα treatment is
well documented,39 these cells were used as a positive control for
TNFα activity and for the immunodetection of NF‐κB effectors.
2.4 | Western immunoblotting
Protein content in cell lysates was determined using the Qubit fluo-
rometer 2.0 (Invitrogen Ltd, Paisley, UK). Proteins in cell lysate sam-
ples were resolved by SDS‐PAGE, alongside a molecular weight
marker (PageRuler Prestained Protein Ladder, Thermo Scientific,
Rockford, USA) after which immunoblotting analysis was performed
as previously described.40 To standardize and normalize across blots,
an aliquot of a random sample was loaded on each gel as an internal
control. Primary and secondary antibodies used are listed in Table 1.
Protein detection was achieved using an enhanced chemiluminescent
(ECL) substrate kit (Thermo Scientific, Rockford, USA) followed by
imaging on the ChemiDoc BioRad ChemiDOC™ digital imager
(BioRad, Hampstead, UK). Band densitometry values were obtained
using Image Lab Software (Bio‐Rad, Hampstead, UK) and the read-
ings were normalized against values of the internal control on each
blot (given arbitrary value of 1) and to the loading control (glycer-
aldehyde 3‐phosphate dehydrogenase (GAPDH).
2.5 | Real‐time quantitative PCR (qPCR)
RNA isolation was carried out using the RNeasy Plus Mini‐Kit (Qia-
gen, Hilden, Germany). Complementary DNA was synthesized from
RNA using the First Strand cDNA Synthesis Kit (Thermo Scientific,
Waltham, USA). Quantitative PCR was performed with the MESA
BLUE qPCR Mastermix Plus Kit for SYBR assay (Low ROX; Eurogen-
tec, Belgium) using a modified version of a previous protocol.41
Reactions were run on a Stratagene MX3000P qPCR System (Strata-
gene, California, USA), with a minimum of three biological replicates
for each experimental condition and three technical replicates for
each cDNA sample. Primer sets used are listed in Table 2. Final val-
ues were expressed relative to a calibrator sample assigned an arbi-
trary value of 1 and normalized to the expression of three
housekeeping genes, beta tubulin, GAPDH and ribosomal protein L5
using the efficiency‐corrected ddCt method. The specificity of ampli-
fication reactions was confirmed by melt curve analysis.
2.6 | Cathepsin enzyme activity assays
Enzymatic activities of cathepsins B, L, S and D were determined in
ARPE‐19 exposed to AGE‐modified MG™ in parallel with ARPE‐19
cells exposed to control MG™ through the use of commercially avail-
able fluorometric based activity assays (Abcam, Cambridge, UK). All
steps in this procedure were performed according to manufacturer's
TABLE 1 Antibodies used for the analysis of protein expression
levels
Antibody Dilution
Anti‐cathepsin B (Abcam) 1:500
Anti‐cathepsin D (Abcam) 1:500
Anti‐cathepsin L (Abcam) 1:500
Anti‐cathepsin S (Abcam) 1:500
Anti‐NF‐κB p65 (Abcam) 1:500
Anti‐Phospho‐NF‐κB p65 Ser536P (Cell Signalling,
Hertfordshire, UK)
1:500
Anti‐IkB‐α (Abcam) 1:500
Anti‐GAPDH (Abcam) 1:500
Secondary horseradish peroxidase (HRP)‐conjugated anti‐
rabbit (Sigma‐Aldrich, Dorset, UK)
1:1000
Secondary horseradish peroxidase (HRP)‐conjugated anti‐
rabbit (Sigma‐Aldrich)
1:2000
TABLE 2 Primers used for gene expression level analysis
Cathepsin B Forward 5′GCTTCGATGCACGGGAACAATG3
Reverse 5′CATTGGTGTGGATGCAGATCCG3′
Cathepsin D Forward 5′GCAAACTGCTGGACATCGCTTG3′
Reverse 5′GCCATAGTGGATGTCAAACGAGG3′
Cathepsin L Forward 5′GAAAGGCTACGTGACTCCTGTG3′
Reverse 5′CCAGATTCTGCTCACTCAGTGAG3
Cathepsin S Forward 5′TGGATCACCACTGGCATCTCTG3′
Reverse 5′GCTCCAGGTTGTGAAGCATCAC3′
Beta tubulin Forward 5′CTGGACCGCATCTCTGTGTACT3′
Reverse 5′GCCAAAAGGACCTGAGCGAACA3′
GAPDH Forward 5′TTGCCCTCAACGACCACTTT3′
Reverse 5′TGGTCCAGGGGTCTTACTCC3′
Ribosomal protein
L5
Forward 5′ATGCTCGGAAACGCTTGGT3′
Reverse 5′GCGCAGACTATCATATCCCCC3′
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protocol with fluorescence measured in black 96‐well plates using
the Fluostar Optima plate reader (BMG Labtech, Aylesbury, UK).
2.7 | Statistical analysis
Data analysis was performed with commercial software Microsoft
Excel (Version 2010, Microsoft UK Ltd, Reading, UK) and GraphPad
Prism (Version 5, GraphPad Software, Inc., USA). A P value ≤0.05
was considered to be significant.
3 | RESULTS
3.1 | Cathepsins expression in RPE cells exposed to
AGE: reduction of cathepsin L protein and activity
levels
An in vitro system that mimics an important phenomenon of the
ageing process, the accumulation of AGE, was used to determine the
effects of ageing on the expression and activity of cathepsins in RPE
cells. ARPE‐19 cells were cultured for 14 days on either untreated
MG™ (NA) or AGE‐modified MG™ (A). Despite a slower rate of
growth, RPE cells grown on AGE‐modified MG™ reached confluence
and presented comparable epithelioid cell morphology by day 14 in
culture (Figure 1A)—the time‐point thus chosen for experimental
measurements. Furthermore, no significant difference in cell number
between control and AGE‐modified MG™ at the 2‐week time‐point
was observed (Figure 1B).
Expression of cathepsins B, L, S and D was demostrated, both by
immunoblotting and real time qPCR, in all ARPE‐19 cell lysates from
these cultures (Figure 2). The analysis of expression showed that
cathepsins L (active form) and S (pro‐ and active forms) protein levels
were decreased in cells grown on AGE‐modified MG™ (Figure 2A).
On the other hand, the aspartic protease cathepsin D (active form)
showed an increase in protein levels in RPE cells grown on AGE‐
modified MG™. The analysis of RNA levels showed no difference for
all cathepsins tested in RPE cells grown on control MG™ vs AGE‐
modified MG™, except for cathepsin S which displayed a decrease
(Figure 2B). This observation indicates that protein alterations of
F IGURE 1 A, Morphology by phase contrast microscopy and growth characteristics of ARPE‐19 cells cultured on non‐modified MG™ (NA)
(I, III and V) or AGE‐modified MG™ (A) (II, IV, VI). Representative image of cell cultures at 24 h post seeding (I, II), day 5 post seeding (III, IV)
and day 14 post‐seeding (V, VI). Cells seeded on control NA MG™ presented a higher rate of growth and reached confluency quicker than the
cells seeded on AGE‐modified MG™. Thus, at day 5 post‐seeding, ARPE‐19 cells had reached a confluent state when grown on control MG,™
whereas cells grown on AGE‐modified MG™ were ~40% confluent (III and IV). By day 14, ARPE‐19 cells grown on both control and AGE‐
modified MG™ were confluent and had developed a cobblestone appearance (V and VI) making this time‐point appropriate for comparison
studies. Scale bar represents 100 μm. B, Graph shows cell counts from ARPE‐19 cells grown on control NA MG™ and AGE‐modified MG™ for
7 and 14 d (average ± SEM, n = 3; Student's t test, ***P ≤ 0.001). At each time‐point, dead cells were washed away using PBS after which
remaining cells were removed via trypsinization and counted using a haemocytometer. At 1 wk, (top graph) a significantly higher amount of
cells were found on control NA MG™ compared to cells found on AGE‐modified MG™. By 2 wk (bottom graph), there was no significant
difference between cell number on both control and AGE‐modified MG™
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cathepsins L and D are most likely because of post‐translational
events whereas the decrease in total cathepsin S protein levels is a
consequence of reduced transcription.
As the amount of protein is a factor that can affect cathepsin
enzymatic activity, we thereafter analysed cathepsin‐linked enzy-
matic activity in RPE cells (Figure 3). When grown on AGE‐modified
MG™, ARPE‐19 cells showed a significant decrease in cathepsin L‐
linked enzymatic activity after 14 days in culture. All other cathep-
sins tested showed no significant changes of their activity level.
Taken together, the data highlighted the significant down‐regulation
of cathepsin L at both protein and importantly at activity level in
ARPE‐19 cells cultured on AGE‐modified substrate.
3.2 | Protein levels of key effectors of the NF‐κB
pathway, p65, phospho‐p65 (Ser536) and IκBα are
altered in RPE cells exposed to AGE
As cathepsin L is known to contribute to the regulation of NF‐κB
signalling, alterations of this enzyme, as demonstrated by this study,
could influence NF‐κB activity. Therefore, we investigated the
effects of AGE on the regulation of NF‐κB regulation by first assess-
ing the overall protein levels of total p65 and phospho‐p65 (Ser536),
as well as the NF‐κB inhibitor IkBα in ARPE‐19 cells.
A significant decrease of both total p65 and phospho‐p65
(Ser536) protein levels (consistent with decreased mRNA levels for
p65, data not shown) was observed in RPE cells exposed to AGE‐
treated Matrigel, compared with control cells cultured in non‐AGEd
conditions (Figure 4A,B). IkBα protein levels were also decreased
in RPE cells exposed to AGE, suggesting an overall decrease in
the NF‐κB signalling pathway in RPE cells exposed to AGE. Fur-
thermore, the ratios of phospho‐p65 (Ser536P)/total p65 and total
p65/IkBα protein levels showed no significant alterations between
cells exposed to AGE and control cells (Figure 4C‐D). The results
indicated a similar decrease in protein and activity levels of these
key effectors of the NF‐κB signalling pathway subsequent to
exposure to the AGEd environment, suggestive of an AGE‐
related cellular response resulting in dampening of this signalling
pathway.
3.3 | Effect of cathepsin L inhibition on the
constitutive expression of NF‐κB signalling effectors
in RPE cells
In order to investigate the potential functional link between cathep-
sin L and regulation of NF‐κB signalling in RPE cells, the protein
levels of total p65, phospho‐p65 (Ser536) and IkBα were measured
and compared in the presence and absence of the irreversible
cathepsin L inhibitor III (Merck Millipore). Optimization of inhibitor
concentration/time course experiments were carried out and showed
that concentrations of 25 μ mol L−1 and 40 μ mol L−1 of cathepsin L
F IGURE 2 Analysis of expression levels of the cysteine proteinases cathepsins B, L, S and the aspartic proteinase cathepsin D in ARPE‐19
cells cultured on non‐modified MG™ (NA) and AGE‐modified MG™ (A) for 14 d. A, Protein levels of cathepsins B, L, S and D were assessed by
immunoblotting. GAPDH immunodetection was used as a loading control and for normalization. Representative Western blots shown, with
graphs presenting average normalized protein expression (active form; arbitrary units ± SEM, minimum of n = 9; Student's t test, *P ≤ 0.05;
**P ≤ 0.01). Cathepsin L (active form) and cathepsin S (pro‐ and active forms) protein levels were significantly reduced in ARPE‐19 cells after
AGE exposure. In addition, cathepsin D (active) levels were significantly up‐regulated in ARPE‐19 cells after AGE exposures. B, mRNA levels of
cathepsins B, L, S and D were analysed by qRT‐PCR. Graphs show average expression normalized against three housekeeping genes as
described in Methods (arbitrary units ±SEM, n = 3; Student's t test, **P ≤ 0.01). No significant changes were observed in mRNA levels for all
cathepsins tested after AGE exposure with the exception of cathepsin S, which showed a significant decrease
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inhibitor were sufficient to inhibit cathepsin L activity for up to
8 hours in RPE cells, with viability unaffected in all conditions. We
therefore used the highest concentration (40 μ mol L−1) and the
longest time‐point (8 hours) for subsequent experiments to ensure
effective and sustained cathepsin L inhibition (Figure 5A). A signifi-
cant decrease of total p65 protein level was observed in ARPE‐19
cells treated with cathepsin L inhibitor III, consistent with a role for
cathepsin L in modulation of NF‐κB signalling (Figure 5B,C). Protein
levels of phospho‐p65 (Ser536) and IkBα were not significantly
altered (although the latter slightly decreased). Thus, the overall out-
come of the cathepsin L inhibition translated into a significant
increase of the phospho‐p65 (Ser536)/total p65 ratio (Figure 5D).
Taken together, these results indicate that the overall decrease of
the total p65 protein pool upon cathepsin L inhibition is accompa-
nied by the enhancement of the proportion of activated p65
(Ser536) in the total p65 cellular pool, thus potentially shifting the
profile of p65 activity, similar to signal priming events.
3.4 | Effect of cathepsin L inhibition on the TNFα‐
induced NF‐κB signalling in RPE cells
After determining that cathepsin L activity contributes to modulation
of p65 protein levels in RPE cells, we next investigated whether the
NF‐κB signalling pathway response to the pro‐inflammatory stimulus
F IGURE 3 Activity analysis of
cathepsins B, L, S and D in ARPE‐19 cells
cultured on non‐modified MG™ (NA) and
AGE‐modified MG™ (A) for 14 d. Activity
levels were determined by fluorescence‐
based activity assays. Cathepsin L activity
was decreased in RPE cells after AGE
exposure. Activity levels of cathepsins B, D
and S remained unchanged in ARPE‐19
cells after AGE exposure. Graphs show
average normalized activity in relative
fluorescence units (RFU) (±SEM, minimum
of n = 5; Student's t test, *P ≤ 0.05)
F IGURE 4 The effect of AGE on NF‐κB pathway effectors in ARPE‐19 cells. A, Protein levels of total p65, phospho‐p65 (Ser536) and IκBα
in ARPE‐19 cells cultured on non‐modified MG™ (NA) and AGE‐modified MG™ (A) for 14 d were successively assessed by immunoblotting.
GAPDH immunodetection was used as a loading control and for normalization. B, Graphs show average normalized protein expression
(arbitrary units ±SEM, n = 10; Student's t test, *P ≤ 0.05; **P ≤ 0.01). Protein levels of total p65, phosph‐p65 (Ser536) and IkBα were all
significantly decreased in ARPE‐19 cells after AGE exposure. C, Ratios of active phospho‐p65 (Ser536)/total p65 and total p65/IkBα showed no
significant difference between non‐AGE and AGE conditions, indicating decrease of respective protein levels at similar rates
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TNFα is altered following inhibition of cathepsin L activity. In both
control (without cathepsin L inhibition) and treated (with cathepsin L
inhibitor III) ARPE‐19 cells, a significant increase of total p65, phos-
pho‐p65 (Ser536) and IkBα protein levels were observed after TNFα
exposure (Figure 6A‐D). Importantly, however, there was no signifi-
cant difference between the fold increase of the ratio of phospho‐
p65 (Ser536)/total p65 induced by TNFα and by cathepsin inhibition
alone (Figure 6E). These data also corroborated the effect of cathep-
sin L inhibition on the profile of active vs total p65 pool demon-
strated for unstimulated conditions (Figure 5D).
3.5 | Effect of AGE on the TNFα‐induced NF‐κB
signalling effectors in RPE cells
After observing that cathepsin L activity modulates the level of
NF‐κB signalling effectors in RPE cells, we sought to determine the
response to TNFα in AGE‐exposed RPE cells, where cathepsin L
activity is decreased. TNFα treatment led to a significant increase in
levels of total p65 only in control cells with overall levels remaining
unaffected in AGE‐exposed cells (Figure 7A,B). Phospho‐p65
(Ser536) and IkBα were significantly increased in both control and
AGE‐exposed cells after exposure to TNFα (Figure 7C,D).
As AGE can independently influence the different NF‐κB effec-
tors, the actual effect of TNFα on the NF‐κB signalling response is
best represented by the phospho‐p65 (Ser536)/total p65 ratio. Thus,
although the ratio of phospho‐p65 (Ser536)/total p65 was signifi-
cantly increased for both control and AGE‐exposed cells after TNFα
treatment (indicating a functional NF‐κB signalling pathway), this
ratio was significantly higher in RPE cells exposed to AGE, indicating
a higher proportion of active p65 in the general pool in an AGE‐con-
taining environment. This is illustrated by the substantial (approxi-
mately six times higher) fold increase of the ratio of phospho‐p65
(Ser536)/total p65 induced by TNFα in the presence of AGE (Fig-
ure 7E). Overall the data show an increased activation of the NF‐κB
signalling in a higher proportion of cells and/or through an enhanced
response to TNFα when cells are exposed to AGE.
4 | DISCUSSION
In this study, we demonstrated that cathepsin L expression and its
enzymatic activity as well as key NF‐κB signalling pathway effectors
decrease in RPE cells exposed to AGE. In addition, we showed that
cathepsin L is involved in modulating the NF‐κB pathway, indicating
that AGE‐induced alterations of NF‐κB effectors may, at least in part,
be a consequence of the changes in cathepsin L levels. Unexpect-
edly, the AGE‐related constitutive dampening of the NF‐κB effectors
created an environment in which cells mounted an increased
F IGURE 5 The effect of cathepsin L activity inhibition on the expression of NF‐κB signalling effectors in RPE cells. A, Evaluation of
cathepsin L inhibitor III concentration and exposure time for effective enzymatic activity inhibition in ARPE‐19 cells. Significant decrease of the
enzymatic activity observed up to 8 h post‐treatment at inhibitor concentrations of 25 μmol L−1 and 40 μmol L−1. B, Immunoblotting analysis
of total p65, phospho‐p65 (Ser536) and IkBα protein levels in ARPE‐19 cells, untreated and treated with 40 μ mol L−1 cathepsin L inhibitor III.
HeLa cells ± TNFα were used as controls. GAPDH immunodetection was used as a loading control and for normalization. C, Comparison of
protein expression of total p65, phospho‐p65 (Ser536) and IkBα normalized to GAPDH level in the absence and presence of cathepsin L
inhibition (arbitrary units ±SEM, minimum of n = 10; Student's t test, *P ≤ 0.05). Protein level of total p65 was significantly decreased in
ARPE‐19 cells in the presence of cathepsin L inhibition (D) Ratio of phospho‐p65 (Ser536)/total p65, indicating the proportion of activated p65
in the total p65 protein pool, in the absence and presence of cathepsin L inhibition (minimum of n = 10; Student's t test, *P ≤ 0.05).
Significant increase in ratio was observed in ARPE‐19 cells in the presence of cathepsin L inhibition compared to control cells. This indicates a
higher amount of activated p65 from the total p65 protein pool
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response to TNFα, indicating that the cells exposed to AGE are more
sensitive and more responsive to pro‐inflammatory conditions. This
data highlights possible key mechanisms in which alterations to
cathepsin L and NF‐κB play a role in the physiology of the ageing
RPE.
The cellular model used in this study exploited the presence of
AGE in the ECM of RPE cells to mimic one aspect of the ageing pro-
cess of these cells. Glycolaldehyde was used to induce AGE formation
on the basement membrane matrix as glycolaldehyde‐derived AGE
adducts involving reactive α‐oxaloaldehydes have been observed in
human BrM.19,42 The use of glycolaldehyde to induce AGE formation
on matrix in vitro, along with the degree of AGE adduct formation and
crosslinking have been described previously.19,37,42 A progressive rise
in AGE has been observed in the BrM with age.18,19 As a direct rela-
tionship between the RPE and BrM exists, AGE deposition on the BrM
may be partially attributed to RPE dysfunction and linked to subse-
quent atrophy and photoreceptor degeneration.
We report here the characterization of expression of cathepsins
B, H, L and D in ARPE‐19 cells and the changes in their expression
in cells exposed to AGE. The most prominent change induced by the
presence of AGE was for cathepsin L, which showed significantly
decreased protein and activity levels (Figures 2 and 3). Being a
potent lysosomal protease, the implications of decreased cathepsin L
activity could have severe impact on crucial proteolysis‐related RPE
functions such as POS degradation and autophagy, processes which
when impaired contribute to the accumulation of cellular debris such
as lipofuscin and ultimately lead to cellular dysfunction.19,43,44 Nota-
bly in the context of RPE function, in addition to core lysosomal
functions, cathepsin L was previously shown to be involved in com-
plement and NF‐κB activity regulation.28,29,45,46
Dysregulated complement plays a key role in AMD development.47
Interestingly, survival of immune cells was shown to be dependent on
intracellular cathepsin L‐mediated cleavage of the key complement
component C3 into biologically active C3a and C3b fragments.45 In
addition, it was also demonstrated that complement factor H (CFH),
an inhibitor of the complement pathway, binds to apoptotic RPE cells
and is internalized where it acts as a co‐factor enhancing cathepsin L‐
mediated cleavage of C3 and opsonization.46 This then aids removal of
damaged/dysfunctional RPE cells as well as preventing excessive
inflammation. As cathepsin L‐mediated cleavage of C3 contributes to
survival of cells, it is possible that a reduction of this enzyme in RPE
cells exposed to AGE, a known inducer of cell death,48 contributes to a
cellular environment unfavourable for RPE survival. Furthermore, dam-
aged/dysfunctional RPE cells would not efficiently be removed
because of reduction in cathepsin L‐mediated cleavage of C3 and sub-
sequent diminished opsonization. An accumulation of dysfunctional
cells may then contribute to biogenesis of material such as drusen and
further exacerbate inflammatory conditions.
Of particular interest and a focus in this study was the role of
cathepsin L in NF‐κB activity regulation. Cathepsin L was shown to
F IGURE 6 The effect of TNFα treatment on the level of NF‐κB signalling effectors in RPE cells after cathepsin L inhibition. A, total p65,
phospho‐p65 (Ser536) and IkBα protein expression determined by Western blotting analysis in ARPE‐19 cells exposed to ± cathepsin L
inhibition and ± TNFα treatment. (B‐D) Graphs show average protein expression normalized to GAPDH (arbitrary units ±SEM, minimum of
n = 8; One way ANOVA followed by Tukey's multiple comparison test, *P ≤ 0.05; ***P ≤ 0.001). E, Ratios of phospho‐p65 (Ser536)/total p65
indicate the proportion of phosphorylated p65 (and thus potentially active) in the total p65 pool in RPE cells; data demonstrates similar fold
increase of these ratios upon TNFα stimulation and cathepsin L inhibition
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have a dual role in NF‐κB regulation, being involved in the activation
as well as the suppression of NF‐κB activity.28,29 Current evidence
supports the idea that increased activation of NF‐κB, as a key tran-
scriptional regulator of genes involved in processes such as inflam-
mation and apoptosis,30,31,49,50 is a driving force behind the ageing
process.51 It is also known that AGE exposure leads to NF‐κB activa-
tion.36 As cathepsin L can regulate NF‐κB activity, it is possible that
AGE exert their effects on the NF‐κB signalling pathway, at least in
part, through modulation of cathepsin L levels.
To test the above hypothesis, we investigated the impact of AGE
on levels of key NF‐κB effectors—p65, phospho‐p65 (Ser536) and
IkBα, and addressed the role of cathepsin L in NF‐κB regulation in
RPE cells through the use of a chemical activity inhibitor. Surpris-
ingly, following exposure to AGE, RPE cells displayed decreased total
p65, phospho‐p65 (Ser536) form and IkBα protein levels, which sug-
gested an overall decrease in the NF‐κB signalling system (Figure 4).
Cathepsin L inhibition led to decreased protein level of total p65 in
RPE cells which suggested that the decrease in cathepsin L activity
may contribute to the decrease of total p65 seen in AGE‐exposed
RPE cells. Notably, however, the overall decrease of the total p65
protein pool upon cathepsin L inhibition was accompanied by the
enhancement of the proportion of activated p65 (P‐Ser536) in the
total p65 cellular pool, thus indicating a shift in the profile of p65
activity.
Alterations in NF‐κB signalling effectors lead to changes in genes
and processes regulated by this pathway. We know that p65
regulates the expression of pro‐apoptotic genes such as p53, a
tumour suppressor that induces cell death.49,50 In previous studies,
AGE exposure (up to 48 hours) of RPE cells was shown to induce
cell death, a response associated with increased oxidative insult.48 In
the 2‐week AGE‐exposed RPE cell culture system investigated in our
study, it was observed that AGE‐exposed cells had a slower rate of
growth but did reach confluence and comparable morphology to
control cells by day 14 (Figure 1). This slower rate of growth could
be explained by the known AGE‐induced impairment of replicative
capacity.37 Furthermore, it is possible that once cells were seeded
onto the AGE‐modified basement membrane, a level of cell death
occurred in the first few days which led to a decrease in cell number
and thus a lag behind controls in reaching confluency. Cells that
manage to survive on the AGE‐modified substrate initiated mecha-
nisms and adapted to their environment enabling them to remain
viable. Decreased NF‐κB activation following cathepsin L inhibition
was linked functionally with protection against apoptosis.28 Thus,
dampening of the NF‐κB signalling pathway, which may at least in
part be because of decreased cathepsin L levels in RPE cells, could
be a protective mechanism that helps remaining cells on the AGE‐
modified basement membrane maintain viability in spite of the
adverse and damaging effects of AGE.
Down‐regulation of NF‐κB activity can also influence the expres-
sion of inflammatory genes such as IL‐1β and IL‐18 and affect
inflammation processes.30,31 Clarification of how inflammation arises
and is modulated in the ageing RPE is crucial for understanding how
F IGURE 7 The effect of TNFα treatment on the response of NF‐κB signalling effectors in RPE cells after AGE exposure. A, Total p65,
phospho‐p65 (Ser536) and IkBα protein expression determined, alongside normalizing GAPDH, by Western blotting analysis of ARPE‐19 cells
cultured on non‐modified MG™ (NA) and AGE‐modified MG™ for 14 d. (B‐D) Average normalized total p65, phospho‐p65 (Ser536) and IkBα
protein expression, respectively (arbitrary units ± SEM, minimum of n = 8; One way ANOVA followed by Tukey's multiple comparison test,
***P ≤ 0.001). E, Fold increase of the ratio phospho‐p65 (Ser536)/total p65 following stimulation with TNFα in cells is augmented in AGE‐
exposed cells
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AMD develops. AGE exposure leading to decreased NF‐κB activity
may indicate that RPE cells are able to mount an initial protective
response against inflammatory stimuli. The idea of cells protecting
themselves from damaging stimuli is in line with the concept of
“para‐inflammation,” an adaptive response to cellular/tissue malfunc-
tion which aims to maintain sufficient functionality.52 However, if
cell/tissue stress persists and is not removed, then cells are tipped
from a para‐ to a chronic inflammatory state.52 Para‐inflammation
was described in the ageing retina as a stress response aimed at
maintaining tissue integrity which is lost during chronic inflammation,
contributing to the development of AMD.53 Our data highlights the
shifting in expression patterns of NF‐κB effectors as key mediators
of inflammation in RPE cells in response to the age‐related ubiqui-
tous factor, AGE. Interestingly, a recent study showed that RPE cells
exposed to AGE for 24 hours displayed up‐regulation and down‐reg-
ulation of different pro‐ and anti‐inflammatory cytokines.54 This
complex pattern of secretion was said to reflect a “para‐inflamma-
tory” response of RPE cells after 1‐day exposure.54
In the present study RPE cells were exposed to AGE for 2 weeks
in order to create a more “chronic” exposure. However, the dampen-
ing of the NF‐κB pathway at this time‐point may still be reflective of
a “para‐inflammatory” survival response as the in vitro model used is
likely to reflect the initial adaptive response of RPE cells to the pres-
ence of AGE. The RPE cells in situ undergo a slow progression of
insult by experiencing cumulative age‐related changes and damage. It
is conceivable that the RPE cells use the para‐inflammatory response
as an initial protective mechanism, but may eventually succumb to
prolonged or enhanced damage associated with a chronic condition.
It should also be pointed out that although traditionally seen as a
pro‐inflammatory mediator, NF‐κB can also regulate anti‐inflamma-
tory genes which add extra complexity to this signalling pathway.55
From a para‐inflammation state, cells can be tipped in a direction
that overwhelms cellular defences via constant or additional stresses
to cause dysfunction. We therefore also investigated the response
to the pro‐inflammatory stimulus TNFα of RPE cells that had been
cathepsin L‐inhibited or AGE exposed. In addition to being an indu-
cer of the NF‐κB pathway, TNFα presents increased expression with
human ageing and in age‐related degenerative diseases such as Alz-
heimer's disease.56 Importantly in relation to the RPE, TNFα was
shown to increase the production and secretion of the angiogenic
VEGF protein, a known contributor to development of wet (neovas-
cular) AMD,57 and anti‐TNFα injections helped improve vision of wet
AMD patients.58
Our data provides experimental evidence that in cells exposed to
AGE, the phospho‐p65 (Ser536)/total NF‐κB p65 ratio is significantly
higher compared to non‐AGE cells when treated with TNFα. This is
particularly important functionally, as the higher proportion of active
p65 in the total cellular pool in an AGE‐exposed environment trans-
lated into a higher fold increase of the ratio of phospho‐p65
(Ser536)/total p65 induced by TNF‐α in the presence of AGE com-
pared to the ratio in the presence of AGE alone (Figure 7E), hence
revealing that “aged” RPE cells mount an increased response to pro‐
inflammatory stimuli. Interestingly, no significant difference between
fold increase of the ratio of phospho‐p65 (Ser536)/total p65 was
observed in cells treated with TNF‐α and cathepsin L inhibition alone
(Figure 6E). This shows that cathepsin L inhibition, which only seems
to influence total p65 levels, is not sufficient to make cells more
responsive to pro‐inflammatory stimuli on its own.
In conclusion, our data indicate that the presence of AGE
adducts, a characteristic of the ageing process, renders RPE cells
more responsive to pro‐inflammatory stimuli and that cells become
more vulnerable and responsive to an inflammatory stimulus in an
“aged” environment. This may not be an RPE‐specific response
because TNFα−induced apoptosis is also enhanced in T cells from
elderly patients compared to young ones.59 Also, bone marrow‐
derived macrophage from aged rats were more responsive to pro‐
inflammatory stimuli compared to young macrophage.60 Thus, collec-
tively data from different types of cells indicate that age‐related pro-
cesses, of which AGE accumulation is just one, directly affect the
cellular response to inflammatory stimuli.
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